Pharmalink AB, a Stockholm, Sweden-based specialty pharma company, has raised SEK 35m in funding.
Backers include existing shareholders, including Industrifonden.
The company intends to use the new funds to further advance its two lead product candidates, Nefecon® and Busulipo™.
Nefecon is a pharmaceutical product developed for patients with IgA nephropathy, the most common form of primary glomerulonephritis and a cause of end-stage renal disease requiring treatment with dialysis or transplantation. Pharmalink is currently focusing on preparing pivotal clinical trials.
Busulipo is being developed to provide a conditioning agent for use prior to hematopoietic stem cell transplantation (HSCT), also often known as bone marrow transplantation. In this case, the company is preparing for late stage clinical trials and for the registration and introduction of Busulipo into key global markets.
Led by Managing Director Johan Häggblad, Pharmalink is also actively in-licensing promising new projects to add to its pipeline.